NONPROFIT, NONPARTISAN PLATFORM OF ACCURATE SCIENCE-BASED SOLUTIONS TO COVID-19

Bio-Rad Laboratories Inc.

Business Name: Bio-Rad Laboratories Inc.
Business Genre:
Business Description:

Bio-Rad develops products for life science research and clinical diagnostic markets. The company serves university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality [3]

City: Hercules
State: CA
Country: USA
Data/Evidence of Effectiveness: “Serum: The Platelia SARS-CoV-2 Total Ab assay showed 100% (27/27) positive percent agreement (95% CI: 98.72- 99.85%) in 27 PCR positive subjects and 99.51% (609/612) negative percent agreement [1] (95% CI: 98.58 – 99.83%) in 612 negative subjects. Plasma: The Platelia SARS-CoV-2 Total Ab assay showed 83.3% (20/24) positive percent agreement (95% CI: 64.15 – 93.32%) in 24 PCR positive subjects and 100% (75/75) negative percent agreement (95% CI: 95.13 – 100%) in 75 negative subjects [1] CI: Confidence Interval “
Complimentary Products Needed to Perform Test: “1. Sterile distilled or deionized water to dilute the concentrated washing solution 2. Sodium hypochlorite (household bleach) and sodium bicarbonate 3. Absorbent paper 4. Adhesive film 5. Gloves and eye / face protection 6. Disposable tubes 7. Precision pipettes or a multipipettor to measure and dispense 10 µL to 1000 µL, 1 mL, 2 mL and 10 mL 8. Graduated cylinders of 25 mL, 50 mL, 100 mL and 1000 mL capacity 9. Microplate washing system 10.Dry-heat incubator, capable of maintaining 37°C ± 2°C 11.Microplate reader equipped with 450 and 620 nm filters 12.Container for biohazardous waste. [1]”
Setting of Care: Research laboratories [1]
Current Status / Clinical Development Stage / Expected Milestones: Authorized under Emergency Use Authorization (EUA) granted 4/29/20 [2]. For in vitro diagnotstic use only [1].
Funding & Ownership : Public [8] First IPO in 1966 [7] net worth as of May 19, 2020 is $13.75B [9].
Business Model: They provide instruments, software, consumables, reagents, and content for the areas of cell biology, gene expression, protein purification, protein quantitation, drug discovery and manufacture, food safety, and science education. Products and solutions are based on technologies to separate, purify, identify, analyze, and amplify biological materials such as antibodies, proteins, nucleic acids, cells, and bacteria. They are a leading global provider of in-vitro diagnostics supplies for blood transfusion, diabetes monitoring, autoimmune, and infectious disease testing markets [3].
IP: N/A
History & Origins : Bio-Rad Laboratories was founded in 1952 by David Schwartz and his wife Alice [7]. The company since then, has expanded to produce diagnostic products for research labs to provide clinical information autoimmune diseases, blood tests, infectious diseases, diabetes monitoring, etc. [7].
Date EUA Issued: 4/29/2020 [2]
Sources: 1. https://www.bio-rad.com/webroot/web/pdf/inserts/CDG/en/IFU_72710_04302020_EUA_EN_US.pdf. 2. https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization. 3. https://www.bio-rad.com/en-us/corporate/about-bio-rad?ID=1003. 4. https://www.bio-rad.com/en-us/corporate/corporate-facts?ID=MR8IQU15. 5. https://www.bio-rad.com/en-us/corporate/newsroom?ID=1006 6. https://www.bio-rad.com/en-us/corporate/corporate-officers?ID=MR8IS7E8Z 7. https://www.bio-rad.com/en-us/corporate/our-history?ID=MR8ISY4VY 8. https://www.crunchbase.com/organization/bio-rad-laboratories#section-overview 9. https://www.macrotrends.net/stocks/charts/BIO/bio-rad-laboratories/net-worth
Organization: “
Norman Schwartz
- Chairman of the Board,
President and Chief Executive Officer [6]
 Andrew Last- 
Executive Vice President,
Chief Operating Officer [6] 
Giovanni Magni
- Executive Vice President,
Chief Strategy Officer [6] 
Ilan Daskal
- Executive Vice President,
Chief Financial Officer [6] 
Timothy S. Ernst
- Executive Vice President,
General Counsel & Secretary [6] 
Mike Crowley- 
Executive Vice President, 
Global Commercial Operations [6] 
Annette Tumolo
- Executive Vice President,
President, Life Science Group [6] 
Dara Wright- 
Executive Vice President,
President, Clinical Diagnostics Group [6] Ronald Hutton- 
Vice President,
Treasurer
 [6] 
Ajit Ramalingam
- Senior Vice President,
Chief Accounting Officer [6]”
No. Tests Per Day: 96 tests/ 90 minutes. So for 24 hours (1440 minutes), (96 x 1440)/90 tests = 1536 tests.
Time to Result: 1 hour 30 mins [1]
Test Sample Type: Serum or plasma from blood [1]
Technology Overview: Platelia SARS-CoV-2 Total Ab is a one-step antigen capture format ELISA for qualitative detection of total anti-SARS-CoV-2 nucleocapsid antibodies (IgM/IgA/IgG) in human serum or plasma samples [1].
Testing Type: Qualitative totaly antibody – IgG, IgA, IgM [1]
Test Category: SEROLOGY
Test Name: Platelia SARS-CoV-2 Total Ab [1]
Clinical Application & Need: The Platelia SARS-CoV-2 Total Ab assay is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV2, indicating recent or prior infection [1]
Age of Company: 1952 [7]

Send Message to listing owner